BCRX - BioCryst Pharmaceuticals, Inc.
| Previous Close | 2.5000 |
| Open | 2.4900 |
| Bid | 2.3500 x 3100 |
| Ask | 2.3900 x 3000 |
| Day's Range | 2.3800 - 2.5500 |
| 52 Week Range | 2.3500 - 9.9500 |
| Volume | 970,862 |
| Avg. Volume | 1,440,062 |
| Market Cap | 263.395M |
| Beta (3Y Monthly) | 1.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1540 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.71 |
- GlobeNewswire
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees options to purchase an aggregate of 103,000 shares of BioCryst common stock on September 30, 2019 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $2.87 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date.
- GlobeNewswire
U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile
With the exercise of the second option, BioCryst plans to deliver a total of 20,000 doses of RAPIVAB, which will add approximately $14 million of non-dilutive capital to the company, by the end of 2019. The RAPIVAB purchase by the HHS Office of the Assistant Secretary for Preparedness and Response will supply the Strategic National Stockpile, the nation’s largest supply of life-saving pharmaceuticals and medical supplies for use in a public health emergency. “RAPIVAB is an important antiviral with proven benefits for influenza patients, and we appreciate the opportunity to fulfill these orders for HHS as they support patients and our national security,” said Jon Stonehouse, chief executive officer of BioCryst.
- GlobeNewswire
BioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2019 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Global Healthcare.
- GlobeNewswire
BioCryst Appoints Helen Thackray, M.D., to Board of Directors
RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed clinical rare disease expert, Helen.
- GlobeNewswire
BioCryst to Present at H.C. Wainwright Global Investment Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the H.C. Wainwright Global.
- Thomson Reuters StreetEvents
Edited Transcript of BCRX earnings conference call or presentation 6-Aug-19 12:30pm GMT
Q2 2019 BioCryst Pharmaceuticals Inc Earnings Call
Motley FoolBiocryst Pharmaceuticals Inc (BCRX) Q2 2019 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2019.
- Zacks
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -42.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
BioCryst Reports Second Quarter 2019 Financial Results
—New drug application for once-daily oral BCX7353 for prophylaxis of hereditary angioedema attacks on-track for submission in Q4 2019— —Data from ongoing Phase 1 trial of oral.
- GlobeNewswire
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees options to purchase an aggregate of 42,000 shares of BioCryst common stock on July 31, 2019 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $3.17 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date.
- Zacks
Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q2 Earnings Expected to Decline
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
BioCryst to Report Second Quarter 2019 Financial Results on August 6
RESEARCH TRIANGLE PARK, N.C., July 23, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2019 financial.
- GlobeNewswire
BioCryst Appoints Megan Sniecinski Chief Business Officer
BioCryst Pharmaceuticals, Inc. (BCRX) today announced the appointment of Megan Sniecinski as chief business officer. Ms. Sniecinski joins BioCryst from PTC Therapeutics, where she served as senior vice president of business operations and program management since June 2017. Over nearly five years at PTC, Ms. Sniecinski played a key role in supporting the diversified growth of PTC’s rare disease pipeline and transformation into a global, fully-integrated biopharmaceutical company.
- GlobeNewswire
Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company has begun enrollment of a Phase 1 trial of BCX9930, an oral Factor D inhibitor discovered and developed by BioCryst, for the treatment of complement-mediated diseases. “An oral Factor D inhibitor would meet a significant unmet medical need for patients with many complement-mediated diseases. The preclinical profile of BCX9930 showed high potency, excellent specificity for Factor D, complete suppression of complement-mediated hemolysis after oral dosing, and a wide safety margin, so we look forward to seeing the clinical results from this Phase 1 trial,” said Dr. William Sheridan, chief medical officer of BioCryst.
- Insider Monkey
Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy?
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has experienced […]
- Thomson Reuters StreetEvents
Edited Transcript of BCRX earnings conference call or presentation 8-May-19 12:30pm GMT
Q1 2019 BioCryst Pharmaceuticals Inc Earnings Call
- GlobeNewswire
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., May 31, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies 2019 Healthcare.
- Motley Fool
Here's Why BioCryst Pharmaceuticals Is Soaring Today
A hedge fund disclosed a sizable stake in the company.
- Benzinga
The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...
